βHB therapy (1.5 mmol/kg/d) in AD model of mice for 28 days suppressed APP expression, enhanced the expression levels of neprilysin, as a degradation enzyme for Aβ, reduced number of senile amyloid plaques, and mitigated soluble and insoluble Aβ42 and Aβ40 (Wu et al., 2019). The gene discussed is APP; the disease is Alzheimer disease.